scPharmaceuticals, Inc. $SCPH Shares Purchased by Kingdon Capital Management L.L.C.

Key Points

• Kingdon Capital Management L.L.C. increased its stake in scPharmaceuticals by 25%, now holding 1,000,000 shares worth $2.63 million after acquiring an additional 200,000 shares.
• After several recent ratings changes, scPharmaceuticals has a consensus rating of "Hold" with an average target price of $12.00.
• scPharmaceuticals reported a quarterly loss of ($0.34) EPS, missing estimates, with revenue of $16.04 million that exceeded expectations of $15.41 million.

Kingdon Capital Management L.L.C. lifted its stake in scPharmaceuticals, Inc. (NASDAQ:SCPH - Free Report) by 25.0% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,000,000 shares of the company's stock after purchasing an additional 200,000 shares during the period. Kingdon Capital Management L.L.C. owned about 1.99% of scPharmaceuticals worth $2,630,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of SCPH. Velan Capital Investment Management LP purchased a new position in scPharmaceuticals in the first quarter valued at $2,413,000. Rice Hall James & Associates LLC boosted its holdings in scPharmaceuticals by 41.3% in the first quarter. Rice Hall James & Associates LLC now owns 1,398,057 shares of the company's stock valued at $3,677,000 after purchasing an additional 408,422 shares during the period. King Luther Capital Management Corp raised its stake in scPharmaceuticals by 9.2% in the first quarter. King Luther Capital Management Corp now owns 3,121,170 shares of the company's stock valued at $8,209,000 after buying an additional 263,260 shares in the last quarter. Apis Capital Advisors LLC raised its stake in scPharmaceuticals by 146.3% in the fourth quarter. Apis Capital Advisors LLC now owns 394,000 shares of the company's stock valued at $1,395,000 after buying an additional 234,000 shares in the last quarter. Finally, Nuveen LLC acquired a new stake in scPharmaceuticals in the first quarter valued at $238,000. 89.52% of the stock is currently owned by hedge funds and other institutional investors.

scPharmaceuticals Price Performance

Shares of NASDAQ:SCPH traded up $0.05 during trading on Thursday, hitting $5.57. 542,933 shares of the stock were exchanged, compared to its average volume of 598,051. The company has a current ratio of 3.85, a quick ratio of 3.14 and a debt-to-equity ratio of 3.86. scPharmaceuticals, Inc. has a 12-month low of $1.94 and a 12-month high of $6.28. The company has a market cap of $296.61 million, a PE ratio of -3.07 and a beta of 0.35. The company has a fifty day moving average price of $4.84 and a two-hundred day moving average price of $3.68.

scPharmaceuticals (NASDAQ:SCPH - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.04). scPharmaceuticals had a negative return on equity of 1,647.86% and a negative net margin of 183.55%.The company had revenue of $16.04 million for the quarter, compared to analyst estimates of $15.41 million. On average, analysts forecast that scPharmaceuticals, Inc. will post -1.53 EPS for the current year.

Wall Street Analyst Weigh In

SCPH has been the topic of a number of analyst reports. HC Wainwright cut scPharmaceuticals from a "strong-buy" rating to a "hold" rating and set a $5.35 price target on the stock. in a research note on Friday, August 29th. Craig Hallum cut scPharmaceuticals from a "buy" rating to a "hold" rating and set a $6.00 price target on the stock. in a research note on Monday, August 25th. Maxim Group cut scPharmaceuticals from a "buy" rating to a "hold" rating in a research note on Monday, August 25th. Finally, Wall Street Zen upgraded scPharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday, August 9th. Three equities research analysts have rated the stock with a Hold rating, Based on data from MarketBeat, scPharmaceuticals presently has a consensus rating of "Hold" and a consensus price target of $7.78.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.